Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6

Anti-Cancer Drugs

Volumn 11, Issue 5, 2000, Pages 353-362

  Ishii, Mineko ^a   Iwahana, Michio ^a   Mitsui, Ikuo ^b   Minami, Megumi ^a   Imagawa, Setsuko ^a   Tohgo, Akiko ^a,b   Ejima, Akio ^a  

^a New Prod Research Laboratories III   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

BCRP; Camptothecin; Drug resistance; DX 8951f; Human lung cancer; P glycoprotein

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DNA TOPOISOMERASE; FLUOROURACIL; GLUTATHIONE; GLYCOPROTEIN P; IRINOTECAN;

ARTICLE; CANCER CELL CULTURE; CROSS RESISTANCE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CISPLATIN; DNA PRIMERS; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; FLUOROURACIL; GLUTATHIONE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; LUNG NEOPLASMS; METABOLIC DETOXICATION, DRUG; NEOPLASM PROTEINS; P-GLYCOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUBULIN; TUBULIN MODULATORS; TUMOR CELLS, CULTURED;

EID: 0033911659     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200006000-00005     Document Type: Article

References (17)

1. 1. Mitsui I, Kumazawa E, Hirota Y, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 1995; 86: 776-82.
2. 2. Joto N, Ishii M, Minami M, Kuga H, Mitsui I, Tohgo A. DX-8951f, a new water-soluble camptothecin analog exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int J Cancer 1997; 72: 680-6.
3. 3. Takiguchi S, Kumazawa E, Shimazoe T, Tohgo A, Kono A. Antitumor effect of DX-8951f, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Jpn J Cancer Res 1997; 88: 760-9.
4. 4. Kumazawa E, Jimbo T, Ochi Y, Tohgo A. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother Pharmacol 1998; 42: 210-20.
5. 5. Abe T, Koike K, Ohga T, et al. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br J Cancer 1995; 72: 418-23.
6. 6. Griffith OW. Determination of glutathione and glutathione disulfide using glutathion reductase and 2-vinylpyridine. Anal Biochem 1980; 106: 207-12.
7. 7. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
8. 8. Kurokawa H, Nishio K, Ishida T, et al. Effect of glutathione depletion on cisplatin resistance in cancer cells transfected with the γ-glutamylcysteine synthetase gene. Jpn J Cancer Res 1997; 88: 108-110.
9. 9. Tsuruo T. Biochemical mechanisms of antitumor drug resistance. Seikagaku 1990; 62: 1144-53.
10. 10. Bhalla K, Huang Y, Tang C, et al. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 1994; 8: 465-75.
11. 11. Gollapudi S, Kim CH, Tran BN, Sangha S, Gupta S. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing H60/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother Pharmacol 1997; 40: 150-8.
12. 12. Maliepaard M, van Gastelen MA, Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59: 4559-63.
13. 13. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999; 59: 4237-41.
14. 14. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665-70.
15. 15. Newkirt K, Heffern J, Solman-Mol E, et al. Glutathione contents but not gamma glutamyl cysteine synthetase mRNA expression predicts cisplatin resistance in head and neck cancer cell lines. Cancer Chemother Pharmacol 1997; 40: 75-80.
16. 16. Esaki T, Nakano S, Masumoto N, Fujishima H, Niho Y. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Cancer 1996; 65: 479-84.
17. 17. Kumazawa E, Tohgo A. Antitumor activity of DX-8951f: a new camptothecin derivative. Exp Opin Invest Drugs 1998; 7: 625-32.